ADMA Biologics sees FY23 revenue $210M plus , consensus $197.45M

ADMA currently anticipates full year 2023 total revenues of $210M or more. This outlook is based on our expectations that the U.S. immune globulin market will continue to grow and there will be further share gains for ADMA‘s commercial products within this end-market landscape. A favorably evolving product mix coupled with the realization of supply chain and manufacturing efficiencies are anticipated to drive further margin improvements throughout the year. As a result, ADMA anticipates generating first-time positive EBITDA during the second half of 2023. During 2023, ADMA expects to complete the buildout and open its tenth plasma collection center and obtain United States Food and Drug Administration licensure for three additional plasma collection centers. Longer term, the Company comprehensively reiterates all previously provided financial targets; however, ADMA notes current business trends are tracking at the upper bound of Company expectations. ADMA plans to provide further details related to its 2023 financial expectations on the fourth quarter and full year 2022 earnings call.